Can methotrexate (MTX) cause eye burning?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 31, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Methotrexate and Eye Burning: Recognition and Management

Yes, methotrexate can cause eye burning as a recognized side effect, which may be related to the drug's presence in tear film and potential ocular surface irritation. 1

Mechanism and Presentation

  • Methotrexate can be secreted in tear film at concentrations equivalent to plasma levels, potentially causing ocular irritation symptoms including burning, pruritus, and dry eye sensation 1
  • Acidic lacrimal secretions (pH 6.5) may contribute to decreased solubility of methotrexate in the conjunctival sac, exacerbating symptoms 1
  • Ocular irritation symptoms typically occur 2-7 days after methotrexate administration 1

Risk Factors and Monitoring

  • Patients on higher doses of methotrexate are more likely to experience ocular side effects 1, 2
  • Patients with decreased tear production may be more susceptible to methotrexate-related eye irritation 1
  • Regular ophthalmic monitoring should be considered for patients reporting eye symptoms while on methotrexate therapy 2

Management Approaches

Prevention Strategies

  • Folic acid supplementation (1-5 mg/day) is recommended for all patients on methotrexate to reduce overall side effects, which may help mitigate ocular symptoms 3
  • Adequate hydration is recommended to improve methotrexate elimination and potentially reduce side effects 4
  • Consider subcutaneous administration of methotrexate instead of oral administration, as this may improve bioavailability and reduce side effects 3

Treatment Options

  • If eye burning occurs:

    1. Consider temporary dose reduction of methotrexate if symptoms are bothersome 5
    2. Use artificial tears for symptomatic relief of dry eye/burning sensation 1
    3. Ensure proper folic acid supplementation (1 mg/day for 6 days/week) 3
    4. Monitor for other signs of methotrexate toxicity that may require intervention 5
  • For severe or persistent symptoms:

    1. Consider temporary discontinuation of methotrexate 5
    2. Ophthalmology consultation to rule out other causes of eye burning 2
    3. Evaluate for more serious ocular complications like optic neuropathy 6

Important Considerations

  • Eye burning is generally a reversible side effect that resolves with dose reduction or discontinuation of methotrexate 1, 2
  • Distinguish between simple irritation and more serious ocular complications like optic neuropathy, which has been reported with methotrexate (though rare) 6
  • Patients should be advised to report eye symptoms promptly as part of the pre-treatment counseling about potential side effects 5
  • Regular monitoring of complete blood count, liver function, and renal function is essential for all patients on methotrexate, regardless of ocular symptoms 5

Clinical Pearls

  • Eye burning symptoms typically appear within days after methotrexate administration and may be recurrent with subsequent doses 1
  • The therapeutic benefit of methotrexate may take 3-12 weeks to become apparent, so early side effects like eye burning should be managed supportively when possible rather than immediately discontinuing therapy 5
  • Patients with pre-existing dry eye syndrome may be more susceptible to methotrexate-related ocular irritation 1
  • NSAIDs used concurrently with methotrexate can increase methotrexate levels and potentially worsen side effects, including ocular symptoms 4

References

Guideline

Management of Methotrexate-Induced Leucopenia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Concurrent Use of Mobic (Meloxicam) with Methotrexate

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Reversible optic neuropathy associated with low-dose methotrexate therapy.

Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society, 2005

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.